Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce that Dr. Atul R. Mahableshwarkar M.D., DLFAPA, has joined the Company as Senior Vice President, Clinical Development. Dr. Mahableshwarkar will lead the development of the CYB003 program, Cybin’s proprietary deuterated psilocybin analog which has received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation for the adjunctive treatment of major depressive disorder.
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones
Cybin to Participate at the 27th Annual Milken Institute Global Conference
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference